{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:44:00Z","timestamp":1794321840360,"version":"4.9.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Abionyx Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sepsis is characterized by a dysregulated immune response and metabolic alterations, including decreased high-density lipoprotein cholesterol (HDL-C) levels. HDL exhibits beneficial properties, such as lipopolysaccharides (LPS) scavenging, exerting anti-inflammatory effects and providing endothelial protection. We investigated the effects of CER-001, an engineered HDL-mimetic, in a swine model of LPS-induced acute kidney injury (AKI) and a Phase 2a clinical trial, aiming to better understand its molecular basis in systemic inflammation and renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We carried out a translational approach to study the effects of HDL administration on sepsis. Sterile systemic inflammation was induced in pigs by LPS infusion. Animals were randomized into LPS (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), CER20 (single dose of CER-001 20\u00a0mg\/kg;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), and CER20\u2009\u00d7\u20092 (two doses of CER-001 20\u00a0mg\/kg;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) groups. Survival rate, endothelial dysfunction biomarkers, pro-inflammatory mediators, LPS, and apolipoprotein A-I (ApoA-I) levels were assessed. Renal and liver histology and biochemistry were analyzed. Subsequently, we performed an open-label, randomized, dose-ranging (Phase 2a) study included 20 patients with sepsis due to intra-abdominal infection or urosepsis, randomized into Group A (conventional treatment,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), Group B (CER-001 5\u00a0mg\/kg BID,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), Group C (CER-001 10\u00a0mg\/kg BID,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), and Group D (CER-001 20\u00a0mg\/kg BID,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095). Primary outcomes were safety and efficacy in preventing AKI onset and severity; secondary outcomes include changes in inflammatory and endothelial dysfunction markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CER-001 increased median survival, reduced inflammatory mediators, complement activation, and endothelial dysfunction in endotoxemic pigs. It enhanced LPS elimination through the bile and preserved liver and renal parenchyma. In the clinical study, CER-001 was well-tolerated with no serious adverse events related to study treatment. Rapid ApoA-I normalization was associated with enhanced LPS removal and immunomodulation with improvement of clinical outcomes, independently of the type and gravity of the sepsis. CER-001-treated patients had reduced risk for the onset and progression to severe AKI (stage 2 or 3) and, in a subset of critically ill patients, a reduced need for organ support and shorter ICU length of stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CER-001 shows promise as a therapeutic strategy for sepsis management, improving outcomes and mitigating inflammation and organ damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The study was approved by the Agenzia Italiana del Farmaco (AIFA) and by the Local Ethic Committee (N\u00b0 EUDRACT 2020\u2013004202-60, Protocol CER-001- SEP_AKI_01) and was added to the EU Clinical Trials Register on January 13, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-023-03057-5","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T21:08:17Z","timestamp":1698872897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project"],"prefix":"10.1186","volume":"21","author":[{"given":"Alessandra","family":"Stasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Franzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Staffieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Carparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Losapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Crovace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lacitignola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cimmarusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Murgolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Stufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesira","family":"Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Sallustio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ribezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Brienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Schirinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pontrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Tupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Barbaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Keyserling-Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Crovace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"4","key":"3057_CR1","doi-asserted-by":"crossref","first-page":"e10128","DOI":"10.15252\/emmm.201810128","volume":"12","author":"JM Cavaillon","year":"2020","unstructured":"Cavaillon JM, Singer M, Skirecki T. Sepsis therapies: learning from 30 years of failure of translational research to propose new leads. EMBO Mol Med. 2020;12(4):e10128.","journal-title":"EMBO Mol Med"},{"issue":"11","key":"3057_CR2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u2013247.","journal-title":"Intensive Care Med"},{"issue":"6","key":"3057_CR3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00134-017-4755-7","volume":"43","author":"R Bellomo","year":"2017","unstructured":"Bellomo R, Kellum JA, Ronco C, Wald R, Martensson J, Maiden M, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43(6):816\u201328.","journal-title":"Intensive Care Med"},{"issue":"23","key":"3057_CR4","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445\u201352.","journal-title":"JAMA"},{"issue":"14","key":"3057_CR5","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"issue":"9","key":"3057_CR6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-013-2967-z","volume":"39","author":"O Joannes-Boyau","year":"2013","unstructured":"Joannes-Boyau O, Honor\u00e9 PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39(9):1535\u201346.","journal-title":"Intensive Care Med"},{"issue":"1","key":"3057_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13054-023-04323-x","volume":"27","author":"C Monard","year":"2023","unstructured":"Monard C, Bianchi N, Poli E, Altarelli M, Debonneville A, Oddo M, et al. Cytokine hemoadsorption with CytoSorb(\u00ae) in post-cardiac arrest syndrome, a pilot randomized controlled trial. Crit Care. 2023;27(1):36.","journal-title":"Crit Care"},{"issue":"19","key":"3057_CR8","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.3390\/ijms231911740","volume":"23","author":"D Jarczak","year":"2022","unstructured":"Jarczak D, Nierhaus A. Cytokine storm-definition, causes, and implications. Int J Mol Sci. 2022;23(19):11740.","journal-title":"Int J Mol Sci."},{"issue":"7","key":"3057_CR9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","volume":"45","author":"W Khovidhunkit","year":"2004","unstructured":"Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169\u201396.","journal-title":"J Lipid Res"},{"key":"3057_CR10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fphar.2015.00244","volume":"6","author":"EE Morin","year":"2015","unstructured":"Morin EE, Guo L, Schwendeman A, Li XA. HDL in sepsis - risk factor and therapeutic approach. Front Pharmacol. 2015;6:244.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3057_CR11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13054-020-02860-3","volume":"24","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Couret D, Tran-Dinh A, Duranteau J, Montravers P, Schwendeman A, et al. High-density lipoproteins during sepsis: from bench to bedside. Crit Care. 2020;24(1):134.","journal-title":"Crit Care"},{"issue":"12","key":"3057_CR12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1194\/jlr.E033407","volume":"53","author":"KR Feingold","year":"2012","unstructured":"Feingold KR, Grunfeld C. Lipids: a key player in the battle between the host and microorganisms. J Lipid Res. 2012;53(12):2487\u20139.","journal-title":"J Lipid Res"},{"issue":"11","key":"3057_CR13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00134-009-1609-y","volume":"35","author":"S Barlage","year":"2009","unstructured":"Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Gl\u00fcck T, et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med. 2009;35(11):1877\u201385.","journal-title":"Intensive Care Med"},{"issue":"8","key":"3057_CR14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1097\/01.CCM.0000171183.79525.6B","volume":"33","author":"JY Chien","year":"2005","unstructured":"Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med. 2005;33(8):1688\u201393.","journal-title":"Crit Care Med"},{"issue":"1","key":"3057_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13613-021-00800-0","volume":"11","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Stern J, Bouzid D, Robert T, Dehoux M, Snauwaert A, et al. Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study. Ann Intensive Care. 2021;11(1):11.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"3057_CR16","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/s41598-021-81638-1","volume":"11","author":"F Begue","year":"2021","unstructured":"Begue F, Tanaka S, Mouktadi Z, Rondeau P, Veeren B, Diotel N, et al. Altered high-density lipoprotein composition and functions during severe COVID-19. Sci Rep. 2021;11(1):2291.","journal-title":"Sci Rep"},{"key":"3057_CR17","doi-asserted-by":"crossref","first-page":"102200","DOI":"10.1016\/j.tmaid.2021.102200","volume":"44","author":"JR Ulloque-Badaracco","year":"2021","unstructured":"Ulloque-Badaracco JR, Hernandez-Bustamante EA, Herrera-A\u00f1azco P, Benites-Zapata VA. Prognostic value of apolipoproteins in COVID-19 patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2021;44:102200.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"3057_CR18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13613-021-00865-x","volume":"11","author":"FW Guirgis","year":"2021","unstructured":"Guirgis FW, Leeuwenburgh C, Moldawer L, Ghita G, Black LP, Henson M, et al. Lipid and lipoprotein predictors of functional outcomes and long-term mortality after surgical sepsis. Ann Intensive Care. 2021;11(1):82.","journal-title":"Ann Intensive Care"},{"issue":"4","key":"3057_CR19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/ALN.0000000000003155","volume":"132","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Gen\u00e8ve C, Zappella N, Yong-Sang J, Planesse C, Louedec L, et al. Reconstituted high-density lipoprotein therapy improves survival in mouse models of sepsis. Anesthesiology. 2020;132(4):825\u201338.","journal-title":"Anesthesiology"},{"issue":"725","key":"3057_CR20","doi-asserted-by":"crossref","first-page":"eabl9322","DOI":"10.1126\/scisignal.abl9322","volume":"15","author":"L Guo","year":"2022","unstructured":"Guo L, Morin EE, Yu M, Mei L, Fawaz MV, Wang Q, et al. Replenishing HDL with synthetic HDL has multiple protective effects against sepsis in mice. Sci Signal. 2022;15(725):eabl9322.","journal-title":"Sci Signal."},{"issue":"5","key":"3057_CR21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.184.5.1601","volume":"184","author":"D Pajkrt","year":"1996","unstructured":"Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996;184(5):1601\u20138.","journal-title":"J Exp Med"},{"issue":"3","key":"3057_CR22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.180.3.1025","volume":"180","author":"MM Wurfel","year":"1994","unstructured":"Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180(3):1025\u201335.","journal-title":"J Exp Med"},{"key":"3057_CR23","doi-asserted-by":"crossref","first-page":"936659","DOI":"10.3389\/fphar.2022.936659","volume":"13","author":"S Faguer","year":"2022","unstructured":"Faguer S, Del Bello A, Danet C, Renaudineau Y, Izopet J, Kamar N. Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: a prospective case study. Front Pharmacol. 2022;13:936659.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3057_CR24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/biomedicines10040754","volume":"10","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Begue F, Veeren B, Tran-Dinh A, Robert T, Tashk P, et al. First Recombinant high-density lipoprotein particles administration in a severe ICU COVID-19 patient, a multi-omics exploratory investigation. Biomedicines. 2022;10(4):754.","journal-title":"Biomedicines."},{"issue":"5","key":"3057_CR25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s13054-014-0520-2","volume":"18","author":"G Castellano","year":"2014","unstructured":"Castellano G, Stasi A, Intini A, Gigante M, Di Palma AM, Divella C, et al. Endothelial dysfunction and renal fibrosis in endotoxemia-induced oliguric kidney injury: possible role of LPS-binding protein. Crit Care. 2014;18(5):520.","journal-title":"Crit Care"},{"key":"3057_CR26","doi-asserted-by":"crossref","first-page":"605212","DOI":"10.3389\/fimmu.2021.605212","volume":"12","author":"A Stasi","year":"2021","unstructured":"Stasi A, Franzin R, Divella C, Sallustio F, Curci C, Picerno A, et al. PMMA-based continuous hemofiltration modulated complement activation and renal dysfunction in lps-induced acute kidney injury. Front Immunol. 2021;12:605212.","journal-title":"Front Immunol"},{"issue":"15","key":"3057_CR27","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.3390\/ijms20153682","volume":"20","author":"G Castellano","year":"2019","unstructured":"Castellano G, Stasi A, Franzin R, Sallustio F, Divella C, Spinelli A, et al. LPS-binding protein modulates acute renal fibrosis by inducing pericyte-to-myofibroblast trans-differentiation through TLR-4 signaling. Int J Mol Sci. 2019;20(15):3682.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"3057_CR28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/ndt\/gft516","volume":"29","author":"C Curci","year":"2014","unstructured":"Curci C, Castellano G, Stasi A, Divella C, Loverre A, Gigante M, et al. Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia\/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant. 2014;29(4):799\u2013808.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3057_CR29","doi-asserted-by":"crossref","first-page":"10753","DOI":"10.1096\/fj.201900351R","volume":"33","author":"F Sallustio","year":"2019","unstructured":"Sallustio F, Stasi A, Curci C, Divella C, Picerno A, Franzin R, et al. Renal progenitor cells revert LPS-induced endothelial-to-mesenchymal transition by secreting CXCL6, SAA4, and BPIFA2 antiseptic peptides. FASEB J. 2019;33(10):10753\u201366.","journal-title":"FASEB J"},{"issue":"1","key":"3057_CR30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ajt.13415","volume":"16","author":"G Castellano","year":"2016","unstructured":"Castellano G, Intini A, Stasi A, Divella C, Gigante M, Pontrelli P, et al. Complement modulation of anti-aging factor klotho in ischemia\/reperfusion injury and delayed graft function. Am J Transplant. 2016;16(1):325\u201333.","journal-title":"Am J Transplant"},{"issue":"11","key":"3057_CR31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/01.LAB.0000097190.56734.FE","volume":"83","author":"K Harada","year":"2003","unstructured":"Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest. 2003;83(11):1657\u201367.","journal-title":"Lab Invest"},{"key":"3057_CR32","doi-asserted-by":"crossref","first-page":"103984","DOI":"10.1016\/j.jprot.2020.103984","volume":"230","author":"S Ciordia","year":"2021","unstructured":"Ciordia S, Alvarez-Sola G, Rull\u00e1n M, Urman JM, \u00c1vila MA, Corrales FJ. Digging deeper into bile proteome. J Proteomics. 2021;230:103984.","journal-title":"J Proteomics"},{"key":"3057_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-1936-0_1","volume":"2420","author":"S Ciordia","year":"2022","unstructured":"Ciordia S, Alvarez-Sola G, Rull\u00e1n M, Urman JM, \u00c1vila MA, Corrales FJ. Bile processing protocol for improved proteomic analysis. Methods Mol Biol. 2022;2420:1\u201310.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"3057_CR34","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.2353\/ajpath.2010.090276","volume":"176","author":"G Castellano","year":"2010","unstructured":"Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010;176(4):1648\u201359.","journal-title":"Am J Pathol"},{"issue":"7","key":"3057_CR35","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.4049\/jimmunol.1501709","volume":"196","author":"IN Baranova","year":"2016","unstructured":"Baranova IN, Souza AC, Bocharov AV, Vishnyakova TG, Hu X, Vaisman BL, et al. Human SR-BI and SR-BII potentiate lipopolysaccharide-induced inflammation and acute liver and kidney injury in mice. J Immunol. 2016;196(7):3135\u201347.","journal-title":"J Immunol"},{"issue":"3","key":"3057_CR36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","volume":"36","author":"F Sallustio","year":"2021","unstructured":"Sallustio F, Curci C, Chaoul N, Font\u00f2 G, Lauriero G, Picerno A, et al. High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transplant. 2021;36(3):452\u201364.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"3057_CR37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"9","key":"3057_CR38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, et al. Effect of serial infusions of CER-001, a pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018;3(9):815\u201322.","journal-title":"JAMA Cardiol"},{"issue":"46","key":"3057_CR39","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"JC Tardif","year":"2014","unstructured":"Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35(46):3277\u201386.","journal-title":"Eur Heart J"},{"key":"3057_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Intern Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Intern Suppl."},{"key":"3057_CR41","doi-asserted-by":"crossref","unstructured":"Zarbock A, Koyner JL, Gomez H, Pickkers P, Forni L, ADQI group. Sepsis-associated acute kidney injury - treatment standard. Nephrol Dial Transplant. 2023:gfad142. Epub ahead of print.","DOI":"10.1093\/ndt\/gfad142"},{"issue":"6","key":"3057_CR42","first-page":"e527","volume":"118","author":"JB Dartiguelongue","year":"2020","unstructured":"Dartiguelongue JB. Systemic inflammation and sepsis. Part I: storm formation. Arch Argent Pediatr. 2020;118(6):e527\u201335.","journal-title":"Arch Argent Pediatr."},{"issue":"11","key":"3057_CR43","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.3390\/ijms22115980","volume":"22","author":"A Stasi","year":"2021","unstructured":"Stasi A, Franzin R, Fiorentino M, Squiccimarro E, Castellano G, Gesualdo L. Multifaced Roles of HDL in Sepsis and SARS-CoV-2 Infection: Renal Implications. Int J Mol Sci. 2021;22(11):5980.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"3057_CR44","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/01.CCM.0000117318.84442.9F","volume":"32","author":"BR Gordon","year":"2004","unstructured":"Gordon BR. Poor outcomes associated with low lipid and lipoprotein levels. Crit Care Med. 2004;32(3):878\u20139.","journal-title":"Crit Care Med"},{"issue":"4","key":"3057_CR45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1566524013666131118113927","volume":"14","author":"SC Gordts","year":"2014","unstructured":"Gordts SC, Singh N, Muthuramu I, De Geest B. Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions. Curr Mol Med. 2014;14(4):481\u2013503.","journal-title":"Curr Mol Med"},{"issue":"1","key":"3057_CR46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.10.018","volume":"232","author":"C Tardy","year":"2014","unstructured":"Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014;232(1):110\u20138.","journal-title":"Atherosclerosis"},{"issue":"2","key":"3057_CR47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejim.2012.10.009","volume":"24","author":"R de Pablo","year":"2013","unstructured":"de Pablo R, Monserrat J, Reyes E, D\u00edaz D, Rodr\u00edguez-Zapata M, de la Hera A, et al. Circulating sICAM-1 and sE-Selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome. Eur J Intern Med. 2013;24(2):132\u20138.","journal-title":"Eur J Intern Med"},{"key":"3057_CR48","doi-asserted-by":"crossref","first-page":"105074","DOI":"10.1016\/j.meegid.2021.105074","volume":"96","author":"Q Qin","year":"2021","unstructured":"Qin Q, Liang L, Xia Y. Diagnostic and prognostic predictive values of circulating sTREM-1 in sepsis: a meta-analysis. Infect Genet Evol. 2021;96:105074.","journal-title":"Infect Genet Evol"},{"issue":"8","key":"3057_CR49","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/s41423-021-00733-5","volume":"18","author":"L Jolly","year":"2021","unstructured":"Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, et al. sTREM-1 is a specific biomarker of TREM-1 pathway activation. Cell Mol Immunol. 2021;18(8):2054\u20136.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3057_CR50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ccc.2017.08.003","volume":"34","author":"R Pool","year":"2018","unstructured":"Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin. 2018;34(1):63\u201380.","journal-title":"Crit Care Clin"},{"issue":"8","key":"3057_CR51","doi-asserted-by":"crossref","first-page":"e0272352","DOI":"10.1371\/journal.pone.0272352","volume":"17","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, De Tymowski C, Stern J, Bouzid D, Zappella N, Snauwaert A, et al. Relationship between liver dysfunction, lipoprotein concentration and mortality during sepsis. PLoS One. 2022;17(8):e0272352.","journal-title":"PLoS One"},{"issue":"8","key":"3057_CR52","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552\u201362.","journal-title":"Intensive Care Med"},{"issue":"10219","key":"3057_CR53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200\u201311.","journal-title":"Lancet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03057-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03057-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03057-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T18:16:06Z","timestamp":1700244966000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03057-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03057-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study was reviewed and approved by the Ethical Committee of the Italian Ministry of Education, University and Research (MIUR) (Prot. n.1234\/2020-PR). The pilot clinical study was approved by the Agenzia Italiana del Farmaco (AIFA) and by the Local Ethic Committee (N\u00b0 EUDRACT 2020\u2013004202-60, Protocol CER-001-SEP_AKI_01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are agreed to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LG received research funding from Abionyx and Sanofi (Granted to his University Department), and received speaker and consultancy fees from Fresenius, Estor, Werfen, Astellas, AstraZeneca, Travere, Sandoz, Baxter, Mundipharma, Pharmadoc, Retrophin, GSK, Novartis, and Chinook. CKP, RB, and CT are employees of Abionyx Pharma. MF received speaker fees from Estor. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}